Slaughter and May advised the underwriters on the global offering and listing of H shares of YiChang HEC ChangJiang Pharmaceutical Co., Ltd

Slaughter and May, Hong Kong, advised on the global offering and listing of H shares of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (YiChang HEC) on the Main Board of the Hong Kong Stock Exchange. YiChang HEC raised approximately HK$1.35 billion (before the exercise of the over-allotment option). Slaughter and May advised the underwriters, including China International Capital Corporation, as to U.S. and Hong Kong laws on the global offering.

YiChang HEC is a PRC pharmaceutical manufacturing company that focuses on the development, manufacturing and sale of pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases and cardiovascular diseases. It was ranked amongst the top 4 pharmaceutical manufacturing companies in 2014 in the anti-influenza virus product market in the PRC in terms of revenue and was ranked No. 1 in the oseltamivir phosphate product category in the PRC in terms of revenue in each of 2013 and 2014.

Dealings in the H shares of YiChang HEC on the Hong Kong Stock Exchange commenced on 29 December 2015.

Benita Yu Partner
John Moore Partner
Jianhao Zheng Counsel
Nicola Lui Associate
Christine Yu Associate